Rick Weissenstein, health care policy analyst at Cowen Washington Research Group looks at the latest in health care policy on Capitol Hill and the administration this month. In this episode, he speaks with Mike McCaughan, Founding Partner of Prevision Policy about what to expect from the FDA advisory committee meeting to discuss the COVID-19 vaccines on October 22nd, how the upcoming election could affect the FDA and the impact of executive orders on drug pricing.
Press play below to listen to their conversation.
Get the Full Report
If you’re already a member of our Research portal, log in.
Log InIf not, reach out to us directly for more information.